Regeneron Pharmaceuticals Inc (REGN) FinancialsREGNFinancialRegeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. (REGN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Sanofi, accounting for 50.7% of total sales, equivalent to $2.17B. Other significant revenue streams include EYLEA HD and EYLEA. Understanding this composition is critical for investors evaluating how REGN navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Regeneron Pharmaceuticals, Inc. maintains a gross margin of 86.56%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 33.11%, while the net margin is 30.23%. These profitability ratios, combined with a Return on Equity (ROE) of 14.19%, provide a clear picture of how effectively REGN converts its operational activities into shareholder value.

In the context of the broader market, REGN competes directly with industry leaders such as GSK and SNY. With a market capitalization of $81.77B, it holds a significant position in the sector. When comparing efficiency, REGN's gross margin of 86.56% stands against GSK's 75.42% and SNY's 69.24%. Such benchmarking helps identify whether Regeneron Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Regeneron reported a Q2 revenue of $4.3 billion, a 17% year-over-year increase, and an adjusted EPS of $14.29, showcasing strong financial performance despite recent setbacks.